On 92 survivals from MI and 150 controls, lipoprotein (a) was quantified. The distribution of frequency of lipoprotein (a) level in MI survivals is of a right skewed distribution. lipoprotein (a) levels are not influenced by sex. MI patients had significantly higher lipoprotein (a) level in comparing with the controls, and their best discriminated value is 15mg%, at this higher level, the odd ratio is 3.22. Result confirmed that lipoprotein (a) is a risk factor of MI
Myocardial Infarction ; Lipoproteins ; risk factors

Descriptive, analytical study were conducted. Patients with coronary disease were measured HDL-C, LDL-C level. Group of patients with normal HDL-C, LDL-C levels were measured ApoA-I, ApoB. Comparision of Apo A-I, ApoB of coronary disease patients group with people without these disease. Study on 272 with coronary artery disease and 151 normal people. 165 and 213 of these patients have normal HDL-C, LDL-C levels respectively. 42.42% patients with normal HDL-C levels have low Apo A-I level and only 7.98% patients with normal LDL-C level have high ApoB
Coronary Vessels ; Serum ; Apolipoprotein A-I ; hospitals

BACKGROUND: Resting heart rate (RHR) is considered as a strong predictor of total mortality and hospitalization due to heart failure in hypertension patients. Bisoprolol fumarate, a second-generation beta-adrenoreceptor blockers (β-blocker) is commonly prescribed drug to manage hypertension. The present study was to retrospectively evaluate changes in the average RHR and its association with cardiovascular outcomes in bisoprolol-treated coronary artery disease (CAD) patients from the CAD treated with bisoprolol (BISO-CAD) study who had comorbid hypertension. METHODS: We performed ad-hoc analysis for hypertension sub-group of the BISO-CAD study (n = 866), which was a phase IV, multination, multi-center, single-arm, observational study carried out from October 2011 to July 2015 across China, South Korea, and Vietnam. Multivariate regression analysis was used to identify factors associated with incidence of composite cardiac clinical outcome (CCCO), the results were presented as adjusted odds ratio (OR) along with 95% confidence interval (CI) and adjusted P value. RESULTS: A total of 681 patients (mean age: 64.77 ± 10.33 years) with hypertension from BISO-CAD study were included in the analysis. Bisoprolol improved CCCOs in CAD patients with comorbid hypertension, with RHR <65 and <70 beats/min compared with RHR ≥65 and ≥75 beats/min, respectively, in the efficacy analysis (EA) set. In addition, it lowered RHR in both intent-to-treat (ITT) and EA groups after 6, 12, and 18 months of treatment. Further, RHR 70 to 74 beats/min resulted in significantly higher risk of CCCOs EA set of patients (adjusted OR: 4.34; 95% CI: 1.19-15.89; P = 0.03). Also, events of hospitalization due to acute coronary syndrome were higher when RHR 69 to 74 beats/min compared to RHR <69 beats/min in ITT patients. CONCLUSION Bisoprolol can effectively reduce RHR in Asian CAD patients with comorbid hypertension and hence, improve CCCO without affecting their blood pressure.